Introduction
============

Upper tract urothelial carcinoma (UTUC) is an uncommon, clinically heterogeneous and potentially fatal disease. UTUC accounts for only 5--10% of urothelial carcinomas ([@b1-mmr-12-05-6752],[@b2-mmr-12-05-6752]) and 60% of UTUCs are invasive at diagnosis compared with only 15% for bladder tumors ([@b1-mmr-12-05-6752],[@b3-mmr-12-05-6752]). The established early diagnostic methods for UTUC, including multi detector computed tomographic urography, magnetic resonance imaging, urinary cytology, cystoscopy and ureteroscopy, are either invasive or lack sensitivity ([@b3-mmr-12-05-6752]). Thus, the majority of UTUC cases are diagnosed at an advanced stage, resulting in poor prognoses. Results from studies on bladder cancer, which is more common and more thoroughly studied, are often extrapolated to UTUC ([@b4-mmr-12-05-6752]); however, molecular markers for the detection of UTUC are largely absent. Individuals with low risk UTUC can partially benefit from conservative therapy ([@b3-mmr-12-05-6752],[@b5-mmr-12-05-6752]), but radical nephroureterectomy is still considered the gold standard for the treatment of localized UTUC ([@b3-mmr-12-05-6752],[@b6-mmr-12-05-6752]). Therefore, correct early diagnosis is critical for designing appropriate treatment schedules to increase survival and decrease morbidity. Early biomarkers that can complement and improve current strategies for UTUC detection should be identified.

MicroRNAs (miRNAs/miRs) are a class of 17--27 nucleotide (nt) single stranded RNA molecules that can regulate gene expression by repressing translation or cleaving RNA transcripts in a sequence specific manner. The biogenesis of miRNA has been comprehensively reported in numerous reviews ([@b7-mmr-12-05-6752],[@b8-mmr-12-05-6752]), and the ability of miRNAs to inhibit the translation of oncogenes and tumor suppressors suggests their involvement in carcinogenesis ([@b9-mmr-12-05-6752],[@b10-mmr-12-05-6752]). miRNAs present in human blood samples are known as circulating miRNAs. Circulating miRNAs have been recently demonstrated to be present in a stable and reproducible state ([@b11-mmr-12-05-6752]). Serum and plasma samples are easily acquired in a relatively non invasive manner, and isolated miRNAs can be readily detected by reverse transcription quantitative polymerase chain reaction (RT qPCR), which is a widely used clinical and laboratory technique. The unique expression profile of serum or plasma miRNA has been used as a fingerprint for various malignancies, including carcinomas of the urinary tract ([@b12-mmr-12-05-6752],[@b13-mmr-12-05-6752]). Extracellular miRNAs, either embedded in microvesicles or protected by RNA binding proteins/lipids, can provide diagnostic, prognostic or even therapeutic targets for UTUC.

However, in spite of the aberrant expression of miRNAs being implicated in the clinical prognosis of human UTUC ([@b14-mmr-12-05-6752]), the global circulating miRNA patterns in UTUC patients have not been studied, to the best of our knowledge. Circulating miRNAs are promising candidates for non invasive cancer testing due to the stability and tissue specificity of miRNAs in the blood. Circulating miRNAs have been recently reported as diagnostic markers for various cancer types ([@b15-mmr-12-05-6752]--[@b18-mmr-12-05-6752]). The present study used the deep sequencing platform Illumina HiSeq™ 2000, followed by RT-qPCR, to systematically and extensively identify circulating miRNAs as a novel class of potent non invasive biomarkers for UTUC.

Materials and methods
=====================

Ethics statement
----------------

The present study was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). Written informed consent was obtained from all participants involved in this study.

Study population, sample collection and serum RNA isolation
-----------------------------------------------------------

The present study collected serum samples from 58 UTUC patients (mean age, 68.0 ± 11.6 years) undergoing radical nephroureterectomy at the First Affiliated Hospital of Nanjing Medical University (Nanjing, China), from 2007 to 2013. A total of 42 matched cancer free controls (mean age, 67.9 ± 9.0 years) were also included. These controls were patients with hematuria who were further diagnosed with urinary tract infection, benign prostate hyperplasia and urinary tract calculi at the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). Clinical and pathological charac teristics, including age, gender, family history of cancer, stage and grade, were recorded and are summarized in [Table I](#tI-mmr-12-05-6752){ref-type="table"}. The diagnosis of UTUC was established according to the results of histopathological analysis. Tumors were graded and classified according to the WHO (2004) and TNM classifications of the International Union Against Cancer (2009) ([@b19-mmr-12-05-6752],[@b20-mmr-12-05-6752]). Blood samples of all patients were drawn within 24 h after admission. The coagulated blood samples were collected in tubes containing a separating gel and clot activator and centri fuged at 1,500 × g for 15 min at 4°C. The supernatant was centrifuged at 1,500 × g for 15 min to precipitate cell debris and stored at −80°C until use. Total RNA of 12 UTUC patients and 12 controls was isolated from 200 *µ*l serum samples using an miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions.

HiSeq 2000 sequencing and bioinformatics analysis
-------------------------------------------------

Small RNAs of 16-30 nt in length were first isolated from the total RNA by size fractionation in a 15% Tris/borate/EDTA urea polyacrylamide gel, and these small RNAs were ligated to an activated 5′ adaptor. A 3′ adaptor was then ligated to the small RNA 5′ adaptor, and RT using a RT primer was performed to create cDNA constructs. The RT reaction was performed using primers that were complementary to the two adaptors. The amplified cDNA constructs were purified and sequenced using an Illumina HiSeq 2000 platform (Illumina, Inc., San Diego, CA, USA) with the following parameters: The adaptor molecule and empty sequence were directly trimmed, and low-quality tags were filtered. Only reads 18--32 bp-reads were selected. All sequences that matched transfer RNA, ribosomal RNA and DNA repeats were filtered. Thus, two types of alignment were generated: Reads uniquely mapped to known miRNAs and reads generating other unknown small RNAs. The expression of miRNAs was calculated, and DEGseq was used to differentially screen the miRNAs between the cases and controls by the criterion of P\<0.001. All of the abovementioned procedures were performed by Shanghai Majorbio Bio-pharm Technology (Shanghai, China).

miRNA quantification by RT-qPCR
-------------------------------

A two-phase case-control study was designed to identify serum miRNAs as potential markers for UTUC. In the training set, miRNAs were measured in serum samples from 12 UTUC patients and 12 controls. In the validation set, miRNAs were measured in serum samples from 46 UTUC patients and 30 controls. miRNAs were prepared using an All-in-One™ miRNA qRT-PCR Detection kit (cat. no. AOMD-Q060; GeneCopoeia-FulenGen, Guangzhou, China) according to the manufacturer\'s instructions. Extracted RNA was reverse-transcribed in the presence of poly-A polymerase with an oligo-dT adaptor. A SYBR green qPCR assay was performed with an Applied Biosystems Step One Plus System (Applied Biosystems, Foster City, USA) with forward primer for the mature miRNA sequence and a universal adaptor reverse primer. The respective validated miRNA-specific forward primer (GeneCopoeia-FulenGen) was used for the qPCR assay. Amplification was performed under the following conditions: 95°C for 10 min, followed by 45 cycles of 95°C for 15 sec, 60°C for 30 sec and 72°C for 40 sec. The expression levels of miRNA were normalized to *RNU6-2* as described previously ([@b21-mmr-12-05-6752]). All reactions, including controls with no template RNA, were performed in triplicate. The relative expression of miRNA compared with *RNU6-2* was calculated using the 2^−ΔCt^ method.

Statistical analysis
--------------------

Student\'s *t*-test or the χ^2^ test were used to determine the differences in the selected demographic variables between the cases and controls. The relative expres sion of miRNA was analyzed using the 2^−ΔΔCt^ method. The Mann Whitney U test was used to compare the expression of serum miRNAs between the different groups. R software (version 3.0.1; MathSoft, Seattle, WA, USA) was used to run unsupervised clustering analysis and principal component analysis (PCA). Sensitivity, specificity and area under the curve (AUC) for serum miRNA levels were determined using receiver operator characteristic (ROC) analysis. All tests were two sided, and P\<0.05 (95% CI) was considered to indicate a statistically significant difference. Statistical analysis was performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA).

Results
=======

Characteristics of the study population
---------------------------------------

The frequency distributions of the selected characteristics of the cases and controls are shown in [Table I](#tI-mmr-12-05-6752){ref-type="table"}. No significant differences in age, gender, tobacco smoking and alcohol consumption were identified between the UTUC patients and controls (P\>0.05). The family history of malignancies was similar between the cases and controls. The clinicopathological characteristics are presented in [Table I](#tI-mmr-12-05-6752){ref-type="table"}.

Unsupervised clustering analysis and PCA
----------------------------------------

The differential expression of miRNAs between the UTUC and control serum samples was analyzed by performing unsupervised clustering that was blinded to the clinical annotations. The dendrogram generated by cluster analysis showed a clear distinction between the UTUC and control samples based on the serum miRNA profile ([Fig. 1](#f1-mmr-12-05-6752){ref-type="fig"}).

PCA was used to classify 24 samples (12 UTUC and 12 control samples) based on the expression profile of 711 miRNAs expressed in all samples. The PCA plot illustrates the global characteristics of these samples ([Fig. 2](#f2-mmr-12-05-6752){ref-type="fig"}). Despite heterogeneity within the two groups, the first principal component (PC1) was able to differentiate the UTUC samples from the control samples, and the difference between the two groups was \>95%.

RT-qPCR analysis of serum miRNAs in UTUC
----------------------------------------

To validate the putative markers identified from the profiling results, the present study confirmed the concentrations of 21 candidate miRNAs, which were selected following HiSeq 2000 sequencing, with a SYBR green-based RT-qPCR assay. The criteria for selecting miRNA for RT-qPCR analysis were as follows: i) Counts of miRNAs \>100 in all sequenced samples; ii) fold change \>2 or \<0.5 and P\<0.001; iii) the absolute value of the coefficient in PC1 \>500; and iv) miRNAs sub-categorized by the unsupervised clustering method. Consequently, 21 miRNAs that met the inclusion criteria were selected for further analysis. The results are summarized in [Table II](#tII-mmr-12-05-6752){ref-type="table"}.

Within the validation set, the miRNAs of individual serum samples from 46 UTUC patients and 30 controls were measured, and only miRNAs with a Ct value \<35 in either the UTUC or control groups were selected for further analysis. Furthermore, miRNAs with a detection rate of \<80% and P\>0.05 were excluded from further analysis. These criteria were used to generate a list of 13 miRNAs (miR-664a-3p, miR-423-5p, miR-431-5p, miR-191-5p, miR-92a-3p, miR-22-3p, miR-26a-5p, miR-33b-3p, miR-16-5p, let-7a-5p, let-7b-5p, let-7f-5p and let-7c) that showed different miRNA patterns between the UTUC patients and controls ([Fig. 3](#f3-mmr-12-05-6752){ref-type="fig"}).

ROC curve analysis
------------------

The ROC curves that were constructed to compare the relative concentrations of the 13 miRNAs between the UTUC patients and controls yielded the following AUCs: miR-664a-3p, 0.998, 95% CI (0.992--1.000); miR-423-5p, 0.802, 95% CI (0.702--0.902); miR-431-5p, 0.933, 95% CI (0.879--0.988); miR-191-5p, 0.814, 95% CI (0.712--0.917); miR-92a-3p, 0.675, 95% CI (0.552--0.797); miR-22-3p, 0.836, 95% CI (0.741--0.931); miR-26a-5p, 0.891, 95% CI (0.861--0.962); miR-33b-3p, 0.879, 95% CI (0.801--0.958); miR-16-5p, 0.821, 95% CI (0.715--0.917); let-7a-5p, 0.725, 95% CI (0.605--0.845); let-7b-5p, 0.856, 95% CI (0.762--0.949); let-7f-5p, 0.642, 95% CI (0.516--0.768); and let-7c, 0.905, 95% CI (0.836--0.974). These results suggested the potential of miRNAs for discriminating patients with UTUC from control subjects ([Fig. 4](#f4-mmr-12-05-6752){ref-type="fig"}).

Association with clinical characteristics
-----------------------------------------

To demonstrate the increase in serum miRNA expression during UTUC development, UTUC cases were further stratified according to tumor stage and grade. The patients were divided into two groups (muscle invasive and non muscle invasive) according to pathological stage, and three groups according to pathological grade. No statistically significant differences were observed among the miRNAs; miR-664a-3p, miR-431-5p, miR-423-5p, miR-191-5p, miR-92a-3p, miR-16-5p and let-7b-5p were all upregulated in the muscle invasive group. Similarly, no statis tically significant difference was identified when members of the UTUC group were stratified according to tumor grade (data not shown).

Discussion
==========

The present study evaluated the use of circulating miRNA levels as diagnostic and prognostic factors for UTUC in order to improve currently used diagnostic tools. The results showed that UTUC was associated with a significant increase in the serum levels of 13 circulating miRNAs, namely miR-664a-3p, miR-423-5p, miR-431-5p, miR-191-5p, miR-92a-3p, miR-22-3p, miR-26a-5p, miR-33b-3p, miR-16-5p, let-7a-5p, let-7b-5p, let-7f-5p and let-7c. Further ROC curve analysis showed that ten of the 13 miRNAs (miR-664a-3p, miR-431-5p, miR-423-5p, miR-191-5p, miR-33b-3p, miR-26a-5p, miR-22-3p, miR-16-5p, let-7b-5p and let-7c) were potentially suitable for distinguishing UTUC individuals from the controls (AUC \>0.8).

Circulating miRNAs are present in body fluids and dysregulated miRNAs may be used as disease markers due to their small size, stability and pivotal involvement in the regulation of cell function ([@b22-mmr-12-05-6752]). Tumor derived miRNAs in serum or plasma are easily accessible and the detection technology is widely used in clinical settings. Therefore, circulating miRNAs may emerge as potentially useful blood based tools for monitoring human cancers, particularly at an early stage ([@b23-mmr-12-05-6752]). In the present study, the deep sequencing platform Illumina HiSeq™ 2000 was used to preliminarily characterize an index for estimating the abundance of circulating miRNAs from 12 UTUC patients and 12 controls as an initial screening stage, allowing for the determination of the differential expression of 21 miRNAs between UTUC patients and controls. Deep sequencing approaches for miRNA analysis are becoming routine, and the number of studies targeting miRNAs as potential diagnostic biomarkers for diseases is increasing ([@b24-mmr-12-05-6752]). The major benefits of next-generation sequencing for miRNA profiling include detection of novel as well as known miRNAs and precise identification of miRNA sequences ([@b25-mmr-12-05-6752]). Deep sequencing technology is an effective high throughput tool for initial serum miRNA screening with high accuracy and sensitivity. However, the sequencing results should be validated by RT-qPCR using a large number of individual serum samples, because the sequencing results were obtained from pooled serum samples and may include inaccurate information caused by individual variations. After the initial stage of sequencing circulating miRNA based cancer biomarkers, the present study used RT-qPCR to assess the relative miRNA expression. Subsequently, a list of 13 miRNAs with differential expression between the UTUC cases (n=46) and controls (n=30) was generated. The present study retrospectively assessed the diagnostic capacity of the 13 miRNAs and identified 10 miRNAs that exhibited significant differences (AUC \>80%) between the UTUC cases and the controls, therefore being suitable for distinguishing between the two groups. Circulating miRNAs identified by deep sequencing technology were recently considered as fingerprints for the diagnosis of other types of solid tumor, including gastric cancer ([@b15-mmr-12-05-6752]), papillary thyroid carcinoma ([@b16-mmr-12-05-6752]), hepatocarcinoma ([@b17-mmr-12-05-6752]) and malignant astrocytomas ([@b18-mmr-12-05-6752]). Furthermore, miRNAs isolated from urine or blood in bladder cancer patients were also reported to show potential as non invasive biomarkers for diagnosis and prognosis ([@b26-mmr-12-05-6752]--[@b28-mmr-12-05-6752]).

Among the 10 serum miRNAs identified in the present study, several have already been reported to function in detecting disease, creating prognosis or monitoring treatment response. The expression of circulating miRNA precursor let-7b was reported to be diverse among various cancer types. Let-7b was found to be upregulated in breast tumors ([@b29-mmr-12-05-6752]) and downregulated in ovarian cancer ([@b30-mmr-12-05-6752]). The same trend was found for the expression of circulating let-7c, which was increased in esophageal cancer ([@b31-mmr-12-05-6752]) but decreased in nasopharyngeal carcinoma patients with poor prognosis ([@b32-mmr-12-05-6752]). Circulating let-7b and let-7c expression is cancer specific. Let-7b is highly expressed in platelets ([@b33-mmr-12-05-6752]), which may obscure the diagnostic value of measuring let-7b expression levels in serum. Circulating miR-22 was first reported in esophageal squamous cell carcinoma (ESCC) and serves as a non invasive biomarker for ESCC diagnosis ([@b34-mmr-12-05-6752]). High expression of miR-22 can explain the lack of response in pemetrexed-treated non small cell lung cancer (NSCLC) patients. However, in primary plasma cell leukemia, miR-22 is associated with a positive clinical outcome ([@b35-mmr-12-05-6752]). One study suggested that circulating miR-431 can contribute to the detection of colorectal cancer ([@b36-mmr-12-05-6752]). The present study found that serum let-7b, miR-22, and miR-431 were suitable for distinguishing UTUC cases from the controls with AUCs of 85.6, 83.6 and 93.3%, respectively. As mentioned above, circulating let-7b, miR-22 and miR-431 have been linked to the pathogenesis of other cancer types, indicating the value of these three miRNAs in detecting cancer, including UTUC.

Circulating miR-16 and miR-191 have been reported as reference genes in colorectal adenocarcinoma ([@b37-mmr-12-05-6752]). However, miR-16 and miR-191 are associated with the pathogenesis of other cancer types, including NSCLC ([@b38-mmr-12-05-6752]) and lymphoma ([@b39-mmr-12-05-6752]). Of note, several serum miRNAs identified in the present study are also correlated with urinary cancers. For instance, serum miR-16 and miR-26a allow for the discrimination of prostate cancer and benign prostate hyperplasia patients with PSA \>2.5 ng/ml (AUCs of 83.7 and 91.8%, respectively) ([@b40-mmr-12-05-6752]). Serum miR-191 expression was found to be 5.3 fold higher in renal cell carcinoma patients than that in controls ([@b41-mmr-12-05-6752]). Plasma miR-33b was significantly lower in bladder cancer cases ([@b28-mmr-12-05-6752]) than that in the controls, whereas the serum expression of miR-33b was enhanced in the UTUC cases in the present study. This disparity should be cautiously interpreted according to the possibly different cellular and molecular mechanisms underlying UTUC and lower tracturothelial carcinoma, even if the pathogenetic similarity of UTUC and bladder cancer has been previously reported ([@b4-mmr-12-05-6752],[@b42-mmr-12-05-6752]). These miRNAs may serve as a \'fingerprint\' to identify the presence of urinary cancers. Thus, the diagnostic capacity of these four circulating miRNAs (miR-16, miR-26a, miR-33b and miR-191) in the precise detection of UTUC may be impaired by their involvement in other urinary cancers. Further studies should be performed to confirm the functions of these four circulating miRNAs in urinary cancers.

In the present study, UTUC was found to be associated with serum miR-423 and miR-664. Circulating miR-423 may be useful as a stable blood based biomarker for numerous diseases, including heart failure ([@b43-mmr-12-05-6752]) and acute graft vs host disease ([@b44-mmr-12-05-6752]). However, few studies have demonstrated the implication of serum miR 423 in cancers. Previous studies have shown that miR-423 is increased in head and neck squamous cell carcinomas ([@b45-mmr-12-05-6752]), and is highly expressed in infiltrating ductal carcinomas in women, who later developed metastasis ([@b46-mmr-12-05-6752]). These findings suggested that miR-423 has a function in cancer development. To the best of our knowledge, no previous study has revealed the association between circulating miR-664 and disease prediction. However, the upregulation of miR-664 contributed to enhanced tumorigenesis in a hepatocellular carcinoma cell line ([@b47-mmr-12-05-6752]), suggesting its potential oncogenic behavior. The lack of results showing the association between cancer and circulating miR-664 and miR-423 levels indicates marked cancer specificity of these two miRNAs in UTUC diagnosis. Of note, the high diagnostic capacity (AUC=99.8%) of serum miR-664 in detecting UTUC may be applied in future studies.

Other molecular markers have also been investigated in samples from UTUC patients using immunohistochemistry or *in situ* hybridization. E cadherin and hypoxia inducible factor 1α are prognostic factors in UTUC, and the expression of human telomerase RNA is a useful indicator for the diagnosis and prognosis of UTUC ([@b48-mmr-12-05-6752]--[@b50-mmr-12-05-6752]). However, these molecular markers are more associated with the prognosis rather than the diagnosis of UTUC, and depend on conventional detection methods. Compared with circulating miRNA detection, the conventional diagnostic methods for UTUC, including ureteros copy, urine cytology, excretory urography and ultrasonography, cause discomfort among patients and are time consuming and invasive. Such methods also lack sensitivity and specificity, which may delay diagnosis and treatment. By contrast, the circulating miRNAs identified in the present study could allow for early diagnosis with high sensitivity and specificity.

However, the results of the present study need to be interpreted with caution, as the diagnosis as UTUC has several limitations. First, as UTUC is an uncommon disease, the sample size was relatively small, which may have limited the diagnostic capacity of serum miRNA. Second, the miRNA expression levels were higher in the case group than those in the control group, even if the initial sequencing stage showed that the levels of several miRNAs were downregulated in the case group. The discrepancy between the results of the two stages may be attributed to the relatively low abundance of reduced miRNAs, which was beyond the threshold of RT-qPCR detection. Third, the results of the present study were based on a retrospective study. Thus, a future prospective cohort is required to validate the results of the present study. Finally, other factors, including race and methodology, possibly affected the final results.

In conclusion, a 10 serum miRNA-based expression profile that was able to accurately discern UTUC individuals from the controls was identified. Although the manner by which UTUC specific miRNAs enter the circulation is unknown, the identified serum miRNAs are useful biomarkers for UTUC detection. Such serum based assays may result in improved screening compared with stool based or endoscopic screening methods. Circular miRNA based screening for UTUC must be tested on large cohorts to confirm and increase their sensitivity and specificity.
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![Unsupervised classification by PCA of cases and control samples. PCA was used to classify 24 samples (12 cases and 12 controls) based on the expression profile of 711 microRNAs expressed in all samples. PCA, principal component analysis; 1, controls; 2, cases.](MMR-12-05-6752-g01){#f2-mmr-12-05-6752}

![Relative levels of 13 serum miRNAs in 46 upper tract urothelial carcinoma patients and 30 control individuals (in the validation sets; mean ± standard deviation). These levels were determined by reverse transcription quantitative polymerase chain reaction analysis. Each point represents the mean result for triplicate samples. miR/miRNA, microRNA; Ct, cycle threshold.](MMR-12-05-6752-g02){#f3-mmr-12-05-6752}

![Receiver operator characteristic curves reflecting the ability of the serum levels of 10 individual miRNAs to distinguish the upper tract urothelial carcinoma cases (n=46) from the controls (n=30) (AUC \>80%). miR/miRNA, microRNA; AUC, area under curve; CI, confidence interval.](MMR-12-05-6752-g03){#f4-mmr-12-05-6752}

###### 

Demographic and clinical features of patients with upper tract urothelial carcinoma and controls in the training and validation sets.

  Variable                                                  Cases (n=58)   Controls (n=42)   P value[a](#tfn1-mmr-12-05-6752){ref-type="table-fn"}          
  --------------------------------------------------------- -------------- ----------------- ------------------------------------------------------- ------ -------
  Age (years)                                                                                                                                               
   \<68                                                     28             48.3              22                                                      52.4   0.685
   ≥68                                                      30             51.7              20                                                      47.6   
  Gender                                                                                                                                                    
   Male                                                     41             29.3              30                                                      71.4   0.936
   Female                                                   17             70.7              12                                                      28.6   
  Tobacco smoking status                                                                                                                                    
   Never                                                    32             55.2              26                                                      61.9   0.501
   Positive[b](#tfn2-mmr-12-05-6752){ref-type="table-fn"}   26             44.8              16                                                      38.1   
  Alcohol consumption status                                                                                                                                
   Never                                                    40             82.8              31                                                      73.8   0.278
   Positive[b](#tfn2-mmr-12-05-6752){ref-type="table-fn"}   18             17.2              11                                                      26.2   
  Family history of cancer                                                                                                                                  
   No                                                       42             72.4              37                                                      88.1   0.057
   Yes                                                      16             27.6              5                                                       11.9   
  Tumor stage                                                                                                                                               
   I                                                        21             36.2                                                                             
   II                                                       14             24.1                                                                             
   III                                                      20             34.5                                                                             
   IV                                                       3              5.2                                                                              
  Tumor grade                                                                                                                                               
   PUNLMP                                                   1              1.7                                                                              
   Low grade                                                17             29.3                                                                             
   High grade                                               40             69.0                                                                             

P= 0.934 according to Student\'s *t* test for age distribution between the cases and controls; two sided χ^2^ test for other selected variables between the cases and controls.

Includes either history of use or present use. PUNLMP, papillary urothelial neoplasia of low malignant potential.

###### 

Differentially expressed miRNAs between serum of patients with upper tract urothelial carcinoma and controls.

  miRNA name        Lowest count in all samples   Fold change (cases vs. controls)   P value   Predicted by
  ----------------- ----------------------------- ---------------------------------- --------- --------------
  has-let-7a-5p     88495                         2.08                               \<0.001   PCA
  has-let-7b-5p     13358                         3.18                               \<0.001   PCA
  has-let-7c        65799                         2.44                               \<0.001   PCA
  has-let-7f-5p     85201                         2.05                               \<0.001   PCA
  has-miR-16-5p     477766                        2.43                               \<0.001   PCA
  has-miR-183-5p    7393                          4.24                               \<0.001   PCA
  has-miR-191-5p    53946                         2.57                               \<0.001   PCA
  has-miR-22-3p     64832                         0.46                               \<0.001   PCA
  has-miR-25-3p     86758                         2.78                               \<0.001   PCA
  hsa miR 26a 5p    14980                         2.33                               \<0.001   PCA
  has-miR-33b-3p    6636                          3.98                               \<0.001   CA
  has-miR-3609      127                           12.68                              \<0.001   CA
  has-miR-370       106                           0.39                               \<0.001   CA
  has-miR-423-5p    9077                          2.48                               \<0.001   PCA
  has-miR-431-5p    169                           0.23                               \<0.001   CA
  hsa-miR-451a      183231                        2.18                               \<0.001   PCA
  hsa-miR-4763-5p   122                           10.81                              \<0.001   CA
  hsa-miR-486-5p    1537466                       2.99                               \<0.001   PCA
  hsa-miR-655       148                           5.18                               \<0.001   CA
  hsa-miR-664a-3p   24258                         8.12                               \<0.001   CA
  hsa-miR-92a-3p    161639                        0.46                               \<0.001   PCA

CA, cluster analysis; PCA, principal components analysis; hsa, *Homo sapiens*; miR/miRNA, microRNA.

###### 

Diagnostic values of 13 miRNAs with regard to detection of UTUC.

  miRNA name        AUC     95% CI         P value   Cut off value[a](#tfn4-mmr-12-05-6752){ref-type="table-fn"}   Sensitivity   Specificity
  ----------------- ------- -------------- --------- ------------------------------------------------------------- ------------- -------------
  hsa-let-7a-5p     0.725   0.605--0.845   0.001     31.55                                                         0.696         0.833
  hsa-let-7b-5p     0.856   0.762--0.949   \<0.001   15.15                                                         0.761         0.867
  hsa-let-7c        0.905   0.836--0.974   \<0.001   1.53                                                          0.739         0.967
  hsa-let-7f-5p     0.642   0.516--0.768   0.037     7.06                                                          0.674         0.700
  hsa-miR-16-5p     0.821   0.725--0.917   \<0.001   290.05                                                        0.739         0.867
  hsa-miR-191-5p    0.814   0.712--0.917   \<0.001   12.92                                                         0.848         0.800
  hsa-miR-22-3p     0.836   0.741--0.931   \<0.001   21.40                                                         0.870         0.800
  hsa-miR-26a-5p    0.891   0.821--0.962   \<0.001   33.17                                                         0.804         0.883
  hsa-miR-33b-3p    0.879   0.801--0.958   \<0.001   313.26                                                        0.717         0.967
  hsa-miR-423-5p    0.802   0.702--0.902   \<0.001   30.01                                                         0.674         0.867
  hsa-miR-431-5p    0.933   0.879--0.988   \<0.001   0.83                                                          0.826         0.933
  hsa-miR-664a-3p   0.998   0.992--1.000   \<0.001   113.74                                                        0.978         1.000
  hsa-miR-92a-3p    0.675   0.552--0.797   0.010     338.44                                                        0.587         0.867

The cut off values of serum miRNAs in UTUC patients vs. control subjects were derived from receiver operator characteristic curves with Youden\'s index. UTUC, upper tract urothelial carcinoma; hsa, *Homo sapiens*; miR/miRNA, microRNA; CI, confidence interval; AUC, area under curve.
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